Introduction and Aims. Despite cannabis use being very common in patients co-infected with HIV and hepatitis C virus (HCV), its effect on these patients' immune systems remains undocumented. Documenting the potential effect of cannabis use on HIV immunological markers would help caregivers make more targeted health recommendations to...
-
March 2017 (v1)Journal articleUploaded on: December 4, 2022
-
March 12, 2012 (v1)Journal article
ABSTRACT: BACKGROUND: Treatment for the hepatitis C virus (HCV) may be delayed significantly in HIV/HCV co-infected patients. Our study aims at identifying the correlates of access to HCV treatment in this population. METHODS: We used 3-year follow-up data from the HEPAVIH ANRS-CO13 nationwide French cohort which enrolled patients living with...
Uploaded on: December 4, 2022 -
2017 (v1)Journal article
Failure of CD4 response (CD4 >500/mm(3)) was associated with age ≥40 years at baseline (P < 0.001), CD4 cell counts ≤500/mm(3) at month 4 (P = 0.016) or month 12 (P < 0.001) and ≥3 months of cART interruption (P = 0.016). Factors associated with failure to achieve complete immunological response (CD4 >500/mm(3) and CD4:CD8 ratio >1) were...
Uploaded on: February 28, 2023 -
September 2017 (v1)Journal article
BACKGROUND AND AIMS:Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use.DESIGN:A...
Uploaded on: December 4, 2022